ClinicalTrials.gg
CompletedNCT01709331Updated May 24, 2024Results posted

A Study of the Efficacy and Safety of Corifollitropin Alfa (MK-8962) in Combination With Human Chorionic Gonadotropin (hCG) in Adult Men With Hypogonadotropic Hypogonadism (HH) (P07937)

A Phase 3 interventional study of Corifollitropin alfa and hCG in Hypogonadism and Hypogonadotropic Hypogonadism, sponsored by Organon and Co. Completed. Open to male participants aged 18 Years to 50 Years. Per ClinicalTrials.gov, last updated 2024-05-24.

Sponsored by Organon and Co · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
18
Allocation
Not applicable
Ages
18 Years to 50 Years
Sex
Male
01

Study summary

This study will assess if corifollitropin alfa (MK-8962), when administered in combination with human chorionic gonadotropin (hCG), will increase testicular volume in men with HH who remain azoospermic after treatment with hCG alone.

Hypothesis: The lower limit of the 95% confidence interval for the geometric mean increase in testicular volume from Day 1 to Week 52 is greater than one.

02

Conditions studied

  • Hypogonadism
  • Hypogonadotropic Hypogonadism

Browse trials for

03

In context

Hypogonadism

320 studies on the registry are indexed under Hypogonadism; 39 are open to participants now.

This study's enrollment of 18 is below the median of 50 across 243 interventional studies indexed under Hypogonadism.

Browse Hypogonadism studies →

Lead sponsor

Organon and Co is the lead sponsor of 505 studies on the registry; none are open to participants now.

Of its 23 completed or terminated interventional studies of FDA-regulated products, 18 (78%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 50 Years
Sexes eligible
Male
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Diagnosed with hypogonadotropic hypogonadism, either congenital or acquired
  • Have low circulating levels of testosterone
  • Have low circulating levels of gonadotropins (follicle stimulating hormone [FSH]; luteinizing hormone)
  • Presence of both scrotal testes
  • Have azoospermia (no measurable level of sperm)
  • Adequate replacement of other pituitary hormones
  • Good general physical and mental health

Exclusion criteria

Exclusion Criteria:

  • Primary hypogonadism, such as Klinefelter's syndrome
  • History of unilateral or bilateral cryptorchidism (maldescended testes)
  • History or presence of testicular pathology of clinical importance (e.g., epididymitis, orchitis, testicular torsion, varicocele stage III, testicular atrophy, occlusive azoospermia, etc), and/or vasectomy
  • Treated with FSH, hCG or gonadotropin-releasing hormone (GnRH) within previous 3 months or for more than 1 month within previous 6 months
  • Proven spermatogenesis with hCG treatment alone
  • Previous unsuccessful attempt with hCG in combination with human menopausal gonadotropin (hMG)/FSH to achieve spermatogenesis
  • Required a dose of hCG of more than 6000 international units (IU) per week in a previous attempt to normalize T levels
  • Untreated pituitary or hypothalamic tumor, or inadequately treated pituitary or hypothalamic tumor that is likely to progress during the study
  • History or presence (known or suspected) of testicular, prostatic or breast cancer
  • Prostate pathology of clinical importance
  • Past or present oncologic treatment (chemo/radiotherapy)
  • Diabetes mellitus
  • , untreated hyperprolactinaemia
  • Uncontrolled non-gonadal endocrinopathies (thyroid, adrenal, pituitary disorders)
  • Tested positive for (HIV), or
  • User of recreational or illicit drugs or has had a recent history (within the past year) of drug abuse or dependence, or increased alcohol consumption
  • Allergy/sensitivity to gonadotropins or its/their
  • Has received within previous 1 month or plans to use: Hormonal preparations other than the study medication, drugs that are known to impair testicular function, agents known to affect sex hormone secretion and/or drugs that are known or suspected to be teratogenic
  • Used any drugs within three months or actively participating in another study
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
18 participants (actual)

Study arms

  • Experimental
    Corifollitropin alfa 150 μg + hCG

    During a 16-week pretreatment phase, participants will receive twice-weekly subcutaneous (SC) injections of hCG 1500 or 3000 international units (IU). Eligible participants will then be enrolled in the combined treatment phase in which they will receive a single dose of corifollitropin alfa 150 μg by SC injection once every 2 weeks for 52 weeks. In addition, eligible participants will continue to receive twice-weekly hCG injections on the same schedule as the pretreatment phase.

    Drug: Corifollitropin alfa · Drug: hCG

Interventions

  • Corifollitropin alfa 150 μg by SC injection, once every 2 weeks for 52 weeks

    Also known as: MK-8962

  • DrughCG

    hCG 1500 or 3000 IU by SC injection twice a week; administered alone for 16 weeks (pre-treatment phase) and then in combination with corifollitropin alfa for 52 weeks (combined treatment phase)

06

What researchers measure

Primary outcomes

  1. Change From Baseline in Log-Transformed Testicular Volume at Week 52

    Participants underwent testicular ultrasound in the pretreatment phase at Weeks -16, -8, -1; and during the combined treatment phase at Baseline (predose, Day 1) and at Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, and 52. The testicular volume was measured as the sum of volumes of left and right testes. The mean change from Day 1 in log-transformed testicular volume was analyzed using a mixed model with a fixed effect for time point and a random effect for the participant. For each time point, the mean change from Day 1 to that time point and the associated 95% confidence interval (CI) was calculated. The geometric mean fold change in testicular volume and its 95% CI was obtained by exponentiation.

    Time frame: Baseline and Week 52

  2. Percentage of Participants With Anti-Corifollitropin Alfa Antibodies

    Blood samples were collected for assessment of anti-corifollitropin alfa antibodies in the pretreatment phase at Week -16 and Week -1; during the combined treatment phase at Weeks 4, 16, 28, 50, 52; and at the post-treatment follow-up visit, which could occur from Week 53 up to Week 57.

    Time frame: Up to Week 57

Secondary outcomes

  1. Percentage of Participants With Induced Spermatogenesis Resulting in a Sperm Count ≥1x10^6/mL at or Before Week 52

    Semen samples were produced by masturbation after at least 48 hours of sexual abstinence and collected for evaluation in the pretreatment phase at Week -1, and during the combined treatment phase at Weeks 16, 28, 40, and 52.

    Time frame: Up to Week 52

07

Results

Posted May 9, 2016

Participant flow

Participant flow — Overall Study
MilestoneCorifollitropin Alfa 150 μg + hCG
Started18
Completed17
Not completed1
Withdrew: Adverse event1

Outcome measures

PrimaryChange From Baseline in Log-Transformed Testicular Volume at Week 52

Participants underwent testicular ultrasound in the pretreatment phase at Weeks -16, -8, -1; and during the combined treatment phase at Baseline (predose, Day 1) and at Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, and 52. The testicular volume was measured as the sum of volumes of left and right testes. The mean change from Day 1 in log-transformed testicular volume was analyzed using a mixed model with a fixed effect for time point and a random effect for the participant. For each time point, the mean change from Day 1 to that time point and the associated 95% confidence interval (CI) was calculated. The geometric mean fold change in testicular volume and its 95% CI was obtained by exponentiation.

Time frame:
Baseline and Week 52
Reported as:
Geometric mean · Fold change
Change From Baseline in Log-Transformed Testicular Volume at Week 52
Fold changeCorifollitropin Alfa 150 μg + hCG
Change From Baseline in Log-Transformed Testicular Volume at Week 522.3 (2.03 to 2.62)
PrimaryPercentage of Participants With Anti-Corifollitropin Alfa Antibodies

Blood samples were collected for assessment of anti-corifollitropin alfa antibodies in the pretreatment phase at Week -16 and Week -1; during the combined treatment phase at Weeks 4, 16, 28, 50, 52; and at the post-treatment follow-up visit, which could occur from Week 53 up to Week 57.

Time frame:
Up to Week 57
Reported as:
Number · Percentage of participants
Percentage of Participants With Anti-Corifollitropin Alfa Antibodies
Percentage of participantsCorifollitropin Alfa 150 μg + hCG
Percentage of Participants With Anti-Corifollitropin Alfa Antibodies0 (52.4 to 93.6)
SecondaryPercentage of Participants With Induced Spermatogenesis Resulting in a Sperm Count ≥1x10^6/mL at or Before Week 52

Semen samples were produced by masturbation after at least 48 hours of sexual abstinence and collected for evaluation in the pretreatment phase at Week -1, and during the combined treatment phase at Weeks 16, 28, 40, and 52.

Time frame:
Up to Week 52
Reported as:
Number · Percentage of participants
Percentage of Participants With Induced Spermatogenesis Resulting in a Sperm Count ≥1x10^6/mL at or Before Week 52
Percentage of participantsCorifollitropin Alfa 150 μg + hCG
Percentage of Participants With Induced Spermatogenesis Resulting in a Sperm Count ≥1x10^6/mL at or Before Week 5277.8 (52.4 to 93.6)

Adverse events

Collected over Up to Week 57. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Corifollitropin Alfa 150 μg + hCG—0/18 (0%)11/18 (61.1%)
Most frequent other events
Showing 10 of 18
Most frequent other events
EventCorifollitropin Alfa 150 μg + hCG
NasopharyngitisInfections and infestations4/18
Oestradiol increasedInvestigations3/18
HeadacheNervous system disorders3/18
Blood testosterone increasedInvestigations2/18
Blood testosterone decreasedInvestigations2/18
Abdominal painGastrointestinal disorders1/18
DiarrhoeaGastrointestinal disorders1/18
HaemorrhoidsGastrointestinal disorders1/18
Seasonal allergyImmune system disorders1/18
ConjunctivitisInfections and infestations1/18

Baseline characteristics

All participants enrolled in the combined treatment phase

Age, Continuous
Age, Continuous(Years)Corifollitropin Alfa 150 μg + hCG
Mean31.5 ± 8.8
Sex: Female, Male
Sex: Female, Male(Participants)Corifollitropin Alfa 150 μg + hCG
Female0
Male18
08

Study locations

No study locations are listed for this record.

09

References and documents

Publications

  • Nieschlag E, Bouloux PG, Stegmann BJ, Shankar RR, Guan Y, Tzontcheva A, McCrary Sisk C, Behre HM. An open-label clinical trial to investigate the efficacy and safety of corifollitropin alfa combined with hCG in adult men with hypogonadotropic hypogonadism. Reprod Biol Endocrinol. 2017 Mar 7;15(1):17. doi: 10.1186/s12958-017-0232-y. PubMed 28270212 ↗

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Feb 2013 to primary completion in Apr 2015, 25 months.

Results were first posted in May 2016, 1 year 1 month after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 16, 2012
First posted
Oct 18, 2012
StartActual
Feb 11, 2013
Primary completionActual
Apr 8, 2015
CompletionActual
Apr 8, 2015
Results first posted
May 9, 2016
Last update
May 24, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 24, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01709331
Lead sponsor
Organon and Co
Responsible party
Sponsor
First posted
Oct 18, 2012
Start date
Feb 11, 2013
Primary completion
Apr 8, 2015
Completion
Apr 8, 2015
Results posted
May 9, 2016
Last update
May 24, 2024

Study contacts

Medical Director
study director · Merck Sharp & Dohme LLC

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Corifollitropin alfa · Chorionic Gonadotropin

Start the discussion